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Background: Canine mast cell tumour proliferation depends to a large extent on the activity of KIT, a tyrosine
kinase receptor. Inhibitors of the KIT tyrosine kinase have recently been introduced and successfully applied as a
therapeutic agent for this tumour type. However, little is known on the downstream target genes of this signaling
pathway and molecular changes after inhibition.
Results: Transcriptome analysis of the canine mast cell tumour cell line C2 treated for up to 72 hours with the
tyrosine kinase inhibitor masitinib identified significant changes in the expression levels of approximately 3500
genes or 16% of the canine genome. Approximately 40% of these genes had increased mRNA expression levels
including genes associated with the pro-proliferative pathways of B- and T-cell receptors, chemokine receptors,
steroid hormone receptors and EPO-, RAS and MAP kinase signaling. Proteome analysis of C2 cells treated for 72
hours identified 24 proteins with changed expression levels, most of which being involved in gene transcription,
e.g. EIA3, EIA4, TARDBP, protein folding, e.g. HSP90, UCHL3, PDIA3 and protection from oxidative stress, GSTT3,
SELENBP1.
Conclusions: Transcriptome and proteome analysis of neoplastic canine mast cells treated with masitinib
confirmed the strong important and complex role of KIT in these cells. Approximately 16% of the total canine
genome and thus the majority of the active genes were significantly transcriptionally regulated. Most of these
changes were associated with reduced proliferation and metabolism of treated cells. Interestingly, several pro-
proliferative pathways were up-regulated, which may represent attempts of masitinib treated cells to activate
alternative pro-proliferative pathways. These pathways may contain hypothetical targets for a combination therapy
with masitinib to further improve its therapeutic effect.
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Canine mast cell tumours (MCT) are currently treated
with one or a combination of four different therapeutic
approaches: surgical, radiation, classical chemotherapy
and the recently introduced tyrosine kinase inhibitors
(TKI) [1-3]. The latter mainly act by inhibiting the stem* Correspondence: robert.klopfleisch@fu-berlin.de
1Department of Veterinary Pathology, Freie Universität Berlin,
Robert-von-Ostertag-Strasse 15, Berlin 14163, Germany
Full list of author information is available at the end of the article
© 2012 Klopfleisch et al.; licensee BioMed Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumcell factor receptor KIT, the activation of which is one of
the most important proliferation stimuli of normal and
neoplastic mast cells [1,4].
KIT is constitutively expressed on normal and neo-
plastic canine mast cells [5]. Due to its central role in
mast cell biology and carcinogenesis a special research
focus has been placed on the understanding of KIT for
canine MCT development, malignant progression and
treatment in recent years. Several KIT mutations have
been identified, which are associated with aberrant KITtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 Effect of masitinib on WST-1 conversion. Masitinib
treatment (100 nM) reduced the metabolic activity of C2 cells by
54% after 24 hours of treatment. The metabolic activity further
decreased up to 40% at 72 hours. Data shown represent the means
+/−SD of five independent experiments with C2 cells, each
performed in three to five wells.
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tor for a subset of canine mast cells [1,6]. For instance,
tandem duplications in the juxtamembrane subunit of
KIT have been identified in up to 12% of all canine MCT
and 40% of malignant grade III MCT [6-8]. This muta-
tion results in a constitutively activated KIT tyrosine kin-
ase and leads to increased malignant behaviour in most
affected tumours [1]. As a consequence TKI have been
introduced for MCT treatment [9-12]. The action of TKI
is not restricted to the tyrosine kinase subunit of KIT but
other tyrosine kinases are also inhibited [12,13]. Never-
theless, the activity of non-KIT tyrosine kinases appear
much lesser relevant for canine mast cell proliferation
and the principle of TKI action in canine MCT is thus
thought to mostly rely on KIT inhibition [1,13].
Masitinib is a tyrosine kinase inhibitor that selectively
targets KIT, the platelet-derived growth factor receptors
α and β (PDGFR-α/β) and the Src family kinases [13].
Masitinib has been successfully used in the treatment of
canine MCT [9,14]. In addition to its direct effects on
MCT by KIT inhibition, in vitro and in vivo, pilot studies
indicate that masitinib also has a potential for chemosen-
sitisation to classic chemotherapeutic agents including
gemcitabine, vinblastine and doxorubicin [15-17].
Despite these ongoing efforts in KIT research in veter-
inary oncology, little is known on the downstream signal
transduction pathways, target genes and cell functions
associated with KIT activity. The present explorative
study therefore aimed at identifying the transcriptional
and translational changes after treatment of neoplastic
canine mast cells with the TKI masitinib using transcrip-
tome and proteome analysis.Results
Cell proliferation, metabolism and death after masitinib
treatment
Treatment of C2 cells with 100 nM masitinib induced a
complete growth arrest with stable cell counts during 72
hours of treatment. In contrast, cell numbers in untreated
C2 cells constantly increased during the experiment with
an almost 3-fold rise of cell counts after 72 hours.
A WST-1 assay was performed to assess mitochondrial
function before exposure, and after 24, 48 and 72 hours
of masitinib exposure (Figure 1). There was an approxi-
mately 60% reduction in WST-1 conversion of masitinib
treated cells at all indicated time points when compared
to the initial activity of the untreated cells. A starting
point analysis was chosen to reduce the influence of
variable cell concentrations of treated and untreated cell
cultures and the different metabolic activity during the
different growth curve phases of untreated cells.
LDH-leakage assay identified a significant increase of
11.4% after 72 hours but no changes after 24 and 48 hours,indicating only a reduced level of cell death and cytotoxicity
at the masitinib concentration used (Figure 2).
Changes in the transcriptome after masitinib treatment
Treatment of C2 cells with masitinib (100nM) induced a
massive change in their global gene expression pattern.
A total of 2,116, 3,087 and 3,502 genes had significant
changes in their expression levels of> 1.5-fold after 12,
24 and 72 h, respectively (Figure 3, Additional file 1).
Approximately 59% of these genes had decreased ex-
pression levels while the rest had increased expression.
Approximately one third of these genes code for nuclear
proteins while 18–26% of the gene products are expressed
in the cytoplasm and in cell organelles (Figure 4).
Most nuclear factors were involved in mitosis and
DNA replication (Figure 5), which were mostly down-
regulated after masitinib treatment. In addition, genes
associated with stress response, glycolysis and the citrate
cycle were significantly down-regulated (Figure 5).
An up-regulation of mRNA expression levels was mostly
observed for genes associated with Golgi apparatus, endo-
plasmic reticulum and lysosomes and genes associated
with apoptosis and proteolysis (Figure 6). Of note, a set of
pro-apoptotic genes were significantly enriched in both,
up-regulated and down-regulated, groups of genes.
Pathway analysis identified a significant down-regulation
of gene expression levels associated with p53, steroid recep-
tor and GTPase-associated signal transduction pathways. In
contrast, there was a time dependent increase in the num-
ber of up-regulated genes associated with signal transduc-
tion pathways during masitinib treatment. After 12 hours
Figure 2 Effect of masitinib on LDH-release. Masitinib induced a
slight increase in LDH release of C2 cells following 72 h treatment
indicating only a mild cytotoxic effect of the masitinib concentration
(100 nM) used. Data shown represent the means+/−SD of six
independent experiments each performed in four to six wells.
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of genes associated with three signal transduction pathways,
i.e. T-cell receptor, insulin receptor and steroid hormone
receptor. At 24 hours genes associated with five additional
pathways were up-regulated, i.e. thyroid receptor, vitamin D
receptor, Ras cascade, IL10 receptor and IGE receptor. Fi-
nally, at 72 hours up-regulation of genes associated with 15
signal transduction pathways were recorded, the aforemen-
tioned pathways and the signalling cascades of the B-cell re-
ceptor, MAP kinase, EGF receptor, focal adhesion, CXCR4
receptor, EPO signalling and PTEN signalling (Figure 7).Figure 3 Microarray analysis of transcriptional changes after masitini
global gene expression pattern with up to 3,500 genes or approximately 16% oA correlation analysis of expression levels with the
different timepoints identified 89 genes with a time
dependent, continuous up-regulation in gene expression
levels during masitinib treatment, including the cyclin-
dependent kinase inhibitor 1A (p21, Cip1), parathyroid
hormone (PTH) and platelet/endothelial cell adhesion
molecule 1 (PECAM1) (Additional file 2). DAVID ana-
lysis identified a significant enrichment of the func-
tional annotations apoptosis, ATM-signalling pathway,
RAS protein signal transduction, aging, B-cell prolifera-
tion and unfolded protein response in this group of
genes. A correlation analysis identified 55 genes that
had a time dependent, continuous decrease in expres-
sion levels during masitinib treatment, including EIF2
and EIF5. Enriched functional annotations in this gene
subset were butyrate and pyruvate metabolism, mito-
chondrial functions, cell migration, apoptosis and mi-
tosis (Additional file 2).Changes in the proteome after masitinib treatment
2D-DIGE and MALDI-TOF analyses of the proteome
after 24 and 72 hours of masitinib treatment identified 24
proteins with significant differences in protein expression
levels when compared to the proteome before masitinib
treatment (Figure 8A and 8B). Three proteins, TAR-DNA
binding protein (TARDBP, 1.52-fold, p=0.012), eukaryotic
translation initiation factor 3 (EIF3, 1.30-fold, p= 0.014)
and the actin related protein 2 (ACTR 2, 1.09-fold,
p= 0.0054) were down-regulated after 24 hours of masiti-
nib treatment (Table 1). Only two proteins, annexin A1
(ANXA1, 1.66-fold, p= 0.0087) and the gelsolin-like cap-
ping protein (CAPG, 1.66-fold, p=0.0039) were up-
regulated after 24 hours of masitinib treatment.b treatment. Masitinib treated cells showed substantial changes in the
f the canine genome having a significant change in transcription activity.
Figure 4 Cellular location of gene products differentially
expressed after masitinib treatment.
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was confirmed by comparing the proteome at 72 hours
of treatment with the pre-treatment proteome. All five
proteins were identified as significantly regulated at 24
hours and having an even increased expression level after
72 hours treatment (Figure 8B, Table 2). Nineteen add-
itional proteins had significant changes in expression
levels after 72 hours treatment (Table 2). Proteins with
the highest down-regulation were the eukaryotic transla-
tion initiation factor 4a (EIF4A, 1.66-fold, p= 0.005), T-
complex protein 1 alpha (TCP1A, 1.63-fold, p= 0.019)
and the inorganic pyrophosphatase 1 (PPA1, 1.25-fold,
p= 0.021). In addition to the two proteins with increased
expression levels after 24 hours, 14 up-regulated proteins
were identified after 72 hours of masitinib treatment. Of
these, iroquois homeobox 6 (IRX6, 1.74-fold, p = 0.0018),
selenium binding protein 1 (SELENBP1, 1.65-fold,
p= 0.0011), ubiquitin carboxyl-terminal esterase L3
(UCHL3, 1.51-fold, p= 0.027) and annexin A6 (ANXA6,
1.50-fold, p= 0.031) had the highest up-regulation in pro-
tein expression levels.Figure 5 Gene functions enriched in the subset of down-regulated ge
stress response, carbohydrate metabolism were significantly enriched in thComparison with the set of genes identified in the tran-
scriptome analysis identified 15 gene products to be
present in the list of mRNA and proteins with significant
changes in expression levels. mRNA expressions from 6
of the 8 down-regulated proteins after masitinib treat-
ment were also down-regulated. Furthermore, mRNA
from 9 of the 15 proteins up-regulated in C2 treated cells
was also present in the transcriptome analysis. However,
only five of the transcripts were up-regulated whereas
four were down-regulated, in contrast to the situation at
the protein level.Discussion
The present study aimed at identifying the transcrip-
tional and translational responses of KIT-mutant canine
mast cells after treatment with the TKI masitinib. To this
end, C2 cells, a cell line with a tandem duplication in the
juxtamembrane unit and thus constitutively activated
KIT, were treated with masitinib and changes in the glo-
bal mRNA and protein expression levels were charac-
terised. Due to the strong dependency of neoplastic mast
cell proliferation on the constitutively activated KIT it
was hypothesized that the observed effects may directly
or indirectly be caused by the inhibition of KIT [1,13].
Treatment of C2 cells with masitinib resulted to a sig-
nificant change in mRNA expression levels of a substan-
tial number of genes. More than 3,500 genes had up-
regulated mRNA expression levels after 72 hours of
masitinib treatment. This gene number corresponds to
approximately 16% of the suspected 22,000 genes in the
canine genome [18]. According to estimations in human
cells, approximately 4,000 genes or 16% of the complete
coding genome is active in a given cell on average [19],
indicating that almost the complete set of active genes
in the C2 cells responds to masitinib treatment. This,
however, is only a very rough estimation since thenes. Genes associated with functions in cell division, anti-apoptosis,
e subset of down-regulated genes after masitinib treatment.
Figure 6 Gene functions enriched in the subset of up-regulated genes. Genes associated with functions in the Golgi-apparatus, the
endoplasmic reticulum and apoptosis were significantly enriched in the subset of up-regulated genes after masitinib treatment.
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analysed neoplastic mast cells.
The initial observation of reduced proliferation and
metabolism of masitinib treated cells lead to the hypoth-
esis that masitinib treatment and thus KIT inhibition
causes a severe shut off of gene activity in treated cells.
The results of the transcriptome analysis however indi-
cate that almost half of the regulated genes were tran-
scriptionally up-regulated. Relatively few of these genes
had a time dependent up- or down-regulation after
masitinib treatment as indicated by the analysis of a po-
tential correlation of the changes in gene expression
levels and increasing treatment times.
The active transcriptional response of C2 cells to masiti-
nib treatment is in accordance with the observation that
there was only a mild increase in LDH release and thus
cell death in the medium of masitinib treated cells even
after 72 hours. C2 cells therefore seem to actively respond
to KIT inhibition with an alternative quantitative andFigure 7 Potentially KIT dependant pathways. Several pro-proliferative
treatment and may thus reflect efforts of treated cells to activate alternativqualitative gene expression pattern to circumvent cell
death. For instance, 15 receptor pathways were up-
regulated after 72 hours of masitinib treatment, most of
which have a potential pro-proliferative activity. It can
thus be hypothesised that those pathways may contain po-
tential targets for combination therapy.
A subsequent proteome analysis identified 24 proteins
with significant changes in protein expression after 72
hours masitinib treatment. 65% of the proteins also had
significant changes in the mRNA expression levels. The
total number of proteins is therefore surprisingly low
when compared to the large number of transcripts
affected. One of the reasons may be a delayed response
of the proteome to the changes in the transcriptome and
changes in mRNA expression levels may therefore not
be reflected after 72 hours [20]. Another point may be
the complete metabolic shut off of treated cells which
may also severely hamper the protein metabolism of the
cells. miRNA as potent regulators of mRNA translationpathways have up-regulated mRNA expression levels after masitinib
e proliferation stimuli and circumvent growth arrest and cell death.
Figure 8 Differentially expressed proteins in masitinib treated C2 cells after 24 (A) and 72 hours (B) when compared to untreated cells.
D1–8: proteins down-regulated in treated cells; U1–U25 (red): proteins up-regulated in treated cells. Two-dimensional difference gel
electrophoresis of cell culture lysates. Isoelectric focusing pH 3–7, gel width 24 cm.
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mRNA and protein expression levels. On the other hand,
two-dimensional difference gel electrophoresis is known
to cover only a fraction of the complete proteome while
hydrophobic proteins, e.g. membrane proteins and
strongly acidic and basic proteins are difficult to separate
and visualise by gel electrophoresis. In addition, the dif-
ferences in the dynamic range of protein and mRNA de-
tection methods also significantly differ and influencethe number and intensity of detected mRNA and protein
species [21].
Conclusions
In conclusion, masitinib treatment of neoplastic mast cells
leads to a massive change in the global mRNA expression
pattern while only few proteins had significant changes in
expression levels after three days of treatment. In contrast
to our initial hypothesis, a surprisingly high number of
Table 1 Down- or up-regulated proteins after 24 hours masitinib treatment
Spot Identified protein AV p-value accession no.
in NCBI







1 TARDBP −1.52 0.012 gi|6678271 (Ho) 45053 5.85 53 1* 4*
2 EIF3 −1.30 0.014 gi|73974369 (Ca) 29504 7.78 92 8 21
3 ACTR2 −1.09 0.0054 gi|73969816 (Ca) 36488 8.21 46 1* 4*
Up-regulated proteins
4 ANXA1 +1.66 0.0087 gi|73946797 (Ca) 38887 5.84 91 12 31
5 CAPG +1.66 0.0039 gi|73980918 (Ca) 39088 6.04 85 6 24
}The listed molecular weights and pI values correspond to the listed accession numbers, which sometimes belong to species other than Canis familiaris (Ca.).
*These proteins were identified by unique peptide sequences determined by MALDI-TOF MS/MS experiments.
Abbreviations: EIF3: eukaryotic translation initiation factor 3; ACTR2: actin-related protein 2; ANXA1: annexin A1; MCP: Macrophage capping protein; Ca: Canis
familiaris; Ho: Homo sapiens.
Table 2 Down- or up-regulated proteins after 72 hours masitinib treatment







1 TARDBP43 −2.62 0.019 gi|6678271 (Ho) 45053 5.85 53 1* 4*
6 EIF4A −1.66 0.005 gi|73966207 (Ca) 44692 5.40 89 15 41
7 TCP1A −1.63 0.019 gi|73945755 (Ca) 60943 5.71 80 9 17
2 EIF3 −1.33 0.012 gi|73974369 (Ca) 29504 7.78 92 8 21
8 PPA1 −1.25 0.021 gi|73953384 (Ca) 33372 5.80 34 1* 2*
9 CCT2 −1.25 0.042 gi|73968673 (Ca) 57737 6.01 80 8 17
3 ACTR2 −1.12 0.019 gi|73969816 (Ca) 36488 8.21 46 1* 4*
10 PSMD6 −1.06 0.040 gi|73981961 (Ca) 99123 9.57 72 10 12
Up-regulated proteins
11 HSP90B1 +1.18 0.048 gi|50979116 (Ca) 22925 6.23 74 5 24
11 GSTT3 +1.20 0.0077 gi|73995693 (Ca) 27793 6.67 98 8 33
12 YWHAZ. +1.22 0.019 gi|73974186 (Ca) 26438 5.00 156 17 52
13 PDIA3 +1.26 0.012 gi|74000349 (Ca) 76474 8.95 161 21 30
14 CORO1A +1.34 0.017 gi|73958506 (Ca) 41955 7.10 52 1* 2*
15 TTC38 +1.34 0.016 gi|73968897 (Ca) 52886 5.67 79 6 12
16 OXCT1 +1.43 0.028 gi|73954281 (Ca) 65275 7.92 90 10 18
17 SEMG1 +1.45 0.017 gi|134093092 (Go) 52065 8.96 83 8 19
18 UROD +1.45 0.016 gi|73977144 (Ca) 35096 5.50 105 9 29
19 ANXA6 +1.50 0.031 gi|73953627 (Ca) 76241 5.47 207 23 32
20 UCHL3 +1.51 0.027 gi|158749588 (Ra) 26278 5.01 74 5 23
21 SELENBP1 +1.65 0.0011 gi|73981582 (Ca) 67142 7.59 89 9 20
22 IRX6 +1.74 0.0018 gi|121484129 (Pa) 24682 8.99 74 5 24
5 CAPG +1.98 0.0036 gi|73980918 (Ca) 39088 6.04 85 6 24
4 ANXA1 +2.58 0.007 gi|73946797 (Ca) 38887 5.84 91 12 31
}The listed molecular weights and pI values correspond to the listed accession numbers, which sometimes belong to species other than Canis familiaris (Ca).
*These proteins were identified by unique peptide sequences determined by MALDI-TOF MS/MS experiments.
Abbreviations: EIF4A: eukaryotic translation initiation factor 4A; TCP-1-alpha: T-complex protein 1, alpha subunit; EIF3: eukaryotic translation initiation factor 3;
ACTR2: actin-related protein 2; EIF3: eukaryotic translation initiation factor 3; HSP-ß1: heat shock protein beta-1; PDI: protein disulfide isomerase-associated 3
precursor; CORO-1A: coronin-1A; UPD: Uroporphyrinogen decarboxylase; ANXA6: annexin A6; MCP: Macrophage capping protein; ANXA1: annexin A1; Ca: Canis
familiaris; Ho: Homo sapiens; Pan: Pan troglodytes; Ra: Rattus; Go: Gorilla.
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efforts to replace KIT activity and circumvent growth ar-
rest by activation of alternative pro-proliferative pathways.
However, as is evident from the long-term follow-up study
of masitinib treatment in dogs with non-resectable MCT,
development of such alternative pathways are by no
means guaranteed [14]. Nonetheless, if present in vivo
these pathways may contain potential candidates to be
identified as targets for a combined therapy with masitinib
to further improve the efficiency of mast cell therapy.
Methods
Cell line
C2 cells were kindly provided by Patrice Dubeuil (Institut
national de la santé et de la recherche médicale
(INSERM), Marseille, France). Cells were cultured in
RPMI-1640 with stable glutamine medium (Biowest,
Nuaillé, France) supplemented with 10% FCS (Biowest,
Nuaillé, France), sodium pyruvate (Biochrome, Berlin,
Germany), MEM non-essential Amino Acids (Biowest,
Nuaillé, France) and penicilline/streptomycine (Gibco,
Darmstadt, Germany) and kept at 5% CO2 and 37°C. Cells
were passaged every 6 to 7 days and rethawed from an ori-
ginal stock every 10 to 12 weeks. In all experiments, cells
from passages 3 through 10 were used. On time point 0
cell culture flasks were incubated with 100 nM masitinib
Mesylate (AB Science, Paris, France) and kept at 5% CO2
and 37°C. Three replicates of RNA and protein were
obtained at time point 0 before and after 12, 24, 48 and
72 hours of masitinib incubation. The supernatant of each
flask was centrifuged at 500 g for 5 minutes and washed
twice with un-supplemented RPMI-1640 medium (Biowest,
Nuaillé, France) with centrifugation steps at 1,000 g for 1
minute. Finally the cell pellet of each flask was equally
divided and used for protein or mRNA isolation,
respectively. Cell pellets were resolved in 250 μl protein
lysis buffer (GE Healthcare, Freiburg, Germany) or 500 μl
RA1 lysis buffer (NucleoSpin RNA; Macherey & Nagel,
Düren, Germany) as previously described. Samples were
stored at −80°C until further use. Cell numbers were
determined at each time point using Trypan Blue exclu-
sion (Biochrome, Berlin, Germany) and viable cells were
counted in a Neubauer microscope counting chamber.
The experiments with the C2 cell line were performed
according to the European, German and local ethical
guidelines of the Freie Universitaet Berlin. Animals,
humans and their tissues were not otherwise involved in
the study presented here.
WST-1 assay
For WST and LDH assays, cells were seeded at a density
of 1.8 × 104 cells / ml in 96-well plates (Greiner,
Frickenhausen, Germany). Mitochondrial activity was
quantified using the Cell Proliferation Reagent WST-1(Roche Diagnostics GmbH, Mannheim, Germany). Fol-
lowing the indicated treatments of cells, 10 μl WST-1 re-
agent was added per well (1:10 final dilution). After a 1
hour incubation at 37°C, the absorbance at 450/630 nm
was measured by using an ELISA reader (Bio-Rad La-
boratories GmbH, München, Germany).
Lactate dehydrogenase release
Lactate dehydrogenase (LDH) activity was determined by
using the CytoTox-ONETM Homogeneous Membrane In-
tegrity Assay (Promega GmbH, Mannheim, Germany), a
fluorimetric method for measuring the release of LDH
from cells with damaged membranes. All reagents were
prepared according to the manufacturer’s instructions.
CytoTox-ONETM reagent (100 μl) was added following
treatments to each well and incubated for a further 10
minutes. Next, 50 μl stop solution was added, the plate was
shaken for 10 seconds, and the fluorescent signal was
recorded at the 560/590nm excitation/emission wavelength
pair by using Fluostar Optima (BMG Labtech GmbH,
Offenburg, Germany). Sample triplicates were treated with
5 μl lysis solution to perform a 100% cell lysis control in
order to determine the maximum amount of LDH.
Protein and mRNA isolation
Proteins were extracted in 250 μl protein lysis buffer con-
taining 7 M urea, 2 M thiourea, and 4% CHAPS (3-(3-
Cholamidopropyl)dimethylammonio-1-propanesulfonate).
Lysates were sonicated twice for 2 minutes and then cen-
trifuged at 2,200 g for 2 minutes. The supernatant was
collected and stored at −80°C until analysis. Protein con-
centrations were determined with the 2-D Quant Kit (GE
Healthcare, Freiburg, Germany). For mRNA isolation
pellets were transferred into 500 μl of RA1 lysis buffer
(NucleoSpin RNA; Macherey & Nagel, Düren, Germany)
containing 5 μl β-mercaptoethanol and homogenized by
pipetting. mRNA was extracted and purified using a
commercial system (NucleoSpin RNA; Macherey &
Nagel, Düren, Germany) [22,23].
RNA quality was controlled using the BioAnalyzer
(Agilent Technologies, USA) and only high quality RNA
(RIN> 9) was used for microarray analyses.
Microarray data analysis
Affymetrix GeneChip hybridization (Canine Genome 2.0
Array) was performed with 2 μg total RNA according to
the manufacturer’s recommendations. Three chips for
each timepoint of treatment and pretreated cells were
stained and washed with the GeneChip Fluidics Station
450 and visualized on an Affymetrix GeneChip Scanner
3000. Microarray data were deposited at the Gene Ex-
pression Omnibus data repository under the number
GSE32657.
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omic Suite Software (Version 6.4, Partek Inc., St. Louis,
USA) and processed by the implemented gcRMA work-
flow (median polish probe set summarization, RMA
background correction, quantile normalization) [24].
Differences in gene expression between samples at the
different time points of masitinib treatment were ana-
lysed by ANOVA and false discovery rate was controlled
by using the q-value method [25]. Differentially
expressed genes were selected by applying a filter of q
< 0.001 and a fold-change of >1.5 in both directions.
Un-named genes were excluded from the list. Hierarch-
ical clustering of the samples and genes was conducted
using Pearson correlation and complete linkage. Change
in expression levels were correlated with the different
timpoints and a partial correlation >0.95 was accepted
as linear correlated.
To supplement the gene annotations of differentially
expressed genes with functional information, BLAST search
and Affymetrix-provided human to canine microarray com-
parisons were used to map canine genes to their human
equivalents as shown before [26,27]. Using the human
equivalents as templates, the DAVID database was queried
for gene ontology information [28]. To study enriched
functional gene families and functional annotation, all
down-regulated and all up-regulated genes were submitted
separately to DAVID [29]. In the case of redundant probes
with a fold-change in the same direction only the probe set
with the highest fold-change was included in further ana-
lyses. Selection criteria for DAVID included a medium
stringency, ≥ 4 probes within a cluster and an enrichment
factor> 1.3. In case of multiple appearances of similar gene
families or functional annotation terms, the cluster with the
higher enrichment factor was selected.
2D-DIGE and MALDI-TOF
Two-dimensional difference gel electrophoresis (2D-DIGE)
was used to quantify and compare the proteome in tripli-
cates of C2 cell pellets before and after 24 and 72 hours of
masitinib treatment. Protein extracts were labelled with
CyDyes (GE Healthcare, Freiburg, Germany) as previously
described [30]. The internal standard was composed of
equal amounts of all protein lysates used. 50 μg of protein
of the respective samples were labelled with 400 pmol of
the respective dye. Two cell pellet probes and the internal
standard were then combined and an equal volume of 2×
sample buffer (7 M urea, 2 M thiourea, 4% CHAPS, 2%
Pharmalyte IPG Buffer, 2% DTT, 0.04% bromophenol blue)
was added. Rehydration buffer (7 M urea, 2 M thiourea, 4%
CHAPS, 2% pharmalyte IPG buffer, 40 mM DTT) was used
to yield a final volume of 450 μl. The Cy-labelled samples
were applied to immobilised non-linear pH gradient (IPG)
strips, pH 3–7 (GE Healthcare, Freiburg, Germany), and
strips were allowed to rehydrate in the dark at roomtemperature overnight. Isoelectric focusing (IEF) was per-
formed using an Ettan IPGphor 3 Isoelectric Focusing Unit
(Ettan IPGphor Manifold; GE Healthcare, Freiburg,
Germany) for a total of 50 kVh at 20°C, 75 μA/strip.
Two steps of equilibration followed IEF: 15 minutes
with equilibration buffer (6 M urea, 30% glycerol, 2%
SDS, and 50 mM Tris, 0.02% bromophenol blue, pH 8.8)
containing 100 mg DTT, followed by 15 minutes with
equilibration buffer containing 250 mg iodoacetamide.
Strips were transferred on top of 24 cm width, 12.5%
SDS-PAGE gels and sealed with 0.5% low-melting-point
agarose. The second-dimension molecular weight separ-
ation was carried out using an Ettan DALTsix Electro-
phoresis Unit (GE Healthcare, Freiburg, Germany).
Running parameters used were 60 mA for 1 hour,
240 mA for 1 hour and 300 mA for 5 hours [31].
CyDye-stained protein spots were visualised with a Ty-
phoon 9400 fluorescence scanner (GE Healthcare,
Freiburg, Germany) at the respective wavelengths for the
three CyDyes. Spot detection, matching and quantifica-
tion of spot intensity were performed using the DeCyder
2D Software, Version 7.0 (GE Healthcare, Freiburg,
Germany). Differences in expression between the different
durations of masitinib treatment were analysed using an
unpaired student’s t test with p-values< 0.05 considered
significant. No multiple testing or FDR adjustment was
done. Gels with 350 μg of protein were silver-stained and
spots were picked for subsequent MS analysis [32].Protein identification by MALDI-TOF-MS
For protein identification by matrix-assisted laser desorp-
tion/ionisation time-of-flight mass spectrometry
(MALDI-TOF-MS) an Ultraflex-II TOF/TOF instrument
(Bruker Daltonics, Bremen, Germany) equipped with a
Smart beam™ laser was used. Peptides were obtained by
trypsin in-gel digestion as previously described [32]. Pro-
tein digests were measured in the reflector mode using
α-cyano-4-hydroxycinnamic acid (CHCA) as matrix. For
the database search, listed contamination peaks from
keratin and autoproteolytic products were excluded for
peptide mass fingerprint database search with the Mascot
server (www.matrixscience.com) in the NCBInr database.
The search was restricted to mammalian sequences and
one missed tryptic cleavage was considered. A mass ac-
curacy of 50−100 ppm was used for the searches.Additional files
Additional file 1: List of genes with significant changes in mRNA
expression levels after 12h, 24 and 72 hours of masitinib treatment.
Additional file 2: Genes with a time-dependent, continuous
increase or decrease in mRNA expression level during masitinib
treatment.
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